An Open-lable, Randomized, Multi center, Phase III Study to Compare the Saftey and Efficacy of TKI258 Versus Sorafenib in Patients with Metastatic Renal Cell Carcinoma After Failure of Anti-angiogenic (VEGF-targeted and mTOR Inhibitor Therapies"

drug protocol number
CTKI258A2302
drug sponsor
Novartis
drug study
TKI258 / Sorafenib
drug trial site
KFSH & RC-R
drug status
Completed
drug phase